← Back to Search

Radiation Therapy

CyberKnife for Prostate Cancer

N/A
Waitlist Available
Led By Afshin Rashtian, MD
Research Sponsored by Riverside Community Hospital, California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

The purpose of this study is to determine the side effects and how effective CyberKnife stereotactic ablative body radiation (SABR) is in patients with prostate cancer. The CyberKnife system is a new type of radiation machine that uses a special system to precisely focus large doses of x-rays on the tumor. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. The purpose of this evaluation is to see if this treatment will help patients with low to intermediate risk prostate cancer and to evaluate the effect of this treatment on the patients' quality of life over time.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
CyberKnife Toxicities in Prostate Cancer
Secondary outcome measures
Cancer Control and Quality of Life (Composite)

Trial Design

1Treatment groups
Experimental Treatment
Group I: CyberKnifeExperimental Treatment1 Intervention
CyberKnife Stereotactic Ablative Body Radiation Therapy

Find a Location

Who is running the clinical trial?

Riverside Community Hospital, CaliforniaLead Sponsor
Afshin Rashtian, MDPrincipal InvestigatorUnaffilated

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer
2013. "CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02070952.
All > Sbrt
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top